Amphotericin B

• 

  Subject Areas on Research

  • 5-fluorocytosine resistance is associated with hypermutation and alterations in capsule biosynthesis in Cryptococcus. 
  • A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis. 
  • A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis. 
  • A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis. 
  • A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis. 
  • AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. 
  • Acute pulmonary decompensation due to amphotericin B in the absence of granulocyte transfusions. 
  • Acute renal failure after lung transplantation: incidence, predictors and impact on perioperative morbidity and mortality. 
  • Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. 
  • Advances in the treatment of invasive neonatal candidiasis. 
  • Aerosolized antifungal prophylaxis: the winds of change? 
  • Amphotericin B alters the affinity and functional activity of the oligopeptide chemotactic factor receptor on human polymorphonuclear leukocytes. 
  • Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. 
  • Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. 
  • Amphotericin B therapy in an anephric patient. 
  • Amphotericin B-induced malignant hypertensive episodes. 
  • Amphotericin B: 30 years of clinical experience. 
  • Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis. 
  • Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. 
  • Antifungal resistance: the clinical front. 
  • Antifungal therapy and outcomes in infants with invasive Candida infections. 
  • Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. 
  • Antifungal treatment in pediatric patients. 
  • Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis. 
  • Aspergillus clavatus endocarditis involving a normal aortic valve following coronary artery surgery. 
  • Atypical localization of Leishmaniasis in an intestinal polyp. 
  • Blastomycosis. 
  • Brain abscess caused by a variety of cladosporium trichoides. 
  • Calcineurin orchestrates dimorphic transitions, antifungal drug responses and host-pathogen interactions of the pathogenic mucoralean fungus Mucor circinelloides. 
  • Candida albicans corpora abscess following penile prosthesis placement. 
  • Candida infective endocarditis: an observational cohort study with a focus on therapy. 
  • Candida meningitis in two children with severe combined immunodeficiency. 
  • Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. 
  • Case 4: Weakness and Headaches in a 14-year-old Boy. 
  • Caspofungin versus amphotericin B for invasive candidiasis. 
  • Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis. 
  • Chemoattractant receptor affinity reflects its ability to transduce different biological responses. 
  • Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. 
  • Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice. 
  • Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. 
  • Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. 
  • Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. 
  • Comparison of caspofungin and amphotericin B for invasive candidiasis. 
  • Cryptococcal meningitis in patients with glioma: a report of two cases. 
  • Cryptococcal meningoencephalitis: time for action. 
  • Cryptococcemia. 
  • Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. 
  • Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. 
  • Delayed recalcitrant fungal endophthalmitis secondary to Curvularia. 
  • Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients. 
  • Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae. 
  • Do not abandon amphotericin B as an antifungal bladder irrigant. 
  • Editorial Commentary: Life-saving Antimicrobial Drugs: What Are We Doing to Pricing and Availability? 
  • Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis. 
  • Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days. 
  • Efficiently killing a sugar-coated yeast. 
  • Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET). 
  • Epidemiological and mycological characteristics of candidemia in patients with hematological malignancies attending a tertiary-care center in India. 
  • Etiologies of illness among patients meeting integrated management of adolescent and adult illness district clinician manual criteria for severe infections in northern Tanzania: implications for empiric antimicrobial therapy. 
  • Evaluation of in vitro antifungal activity of LY121019. 
  • Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. 
  • Failure of amphotericin B colloidal dispersion in the treatment of paracoccidioidomycosis. 
  • Fungal infection following renal transplantation. 
  • Fungal phospholipase activity and susceptibility to lipid preparations of amphotericin B. 
  • Generalized microsporum audoninii infection and depressed cellular immunity associated with a missing plasma factor required for lymphocyte blastogenesis. 
  • Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. 
  • Heterothallic mating in Mucor irregularis and first isolate of the species outside of Asia. 
  • In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. 
  • In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols. 
  • In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. 
  • Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. 
  • Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. 
  • Invasive Curvularia Infection in Pediatric Patients With Hematologic Malignancy Identified by Fungal Sequencing. 
  • Ion channel behavior of amphotericin B in sterol-free and cholesterol- or ergosterol-containing supported phosphatidylcholine bilayer model membranes investigated by electrochemistry and spectroscopy. 
  • Is it time to abandon the use of amphotericin B bladder irrigation? 
  • Itraconazole or Amphotericin B for Talaromycosis. 
  • Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. 
  • Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia. 
  • Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. 
  • Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. 
  • Liposomal amphotericin B: clinical experience and perspectives. 
  • Management of invasive mycoses in hematology patients: current approaches. 
  • Molecular umbrella-amphotericin B conjugates. 
  • Mortality rates in comparative trials of formulations of amphotericin B. 
  • Mucormycosis after open fracture injury. 
  • Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. 
  • Necrotizing pulmonary aspergillosis with oxalosis. 
  • Neonatal candidiasis: prophylaxis and treatment. 
  • New antifungal agents. 
  • Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. 
  • Old and new: appropriate dosing for neonatal antifungal drugs in the nursery. 
  • Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. 
  • Outcome of lung transplantation in patients with mycetomas. 
  • Outcomes of cryptococcosis in renal transplant recipients in a less-resourced health care system. 
  • Penile cryptococcosis with review of mycotic infections of penis. 
  • Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. 
  • Pharmacologic manipulation of leukocyte chemotaxis. Present knowledge and future trends. 
  • Pharmacotherapy of disseminated histoplasmosis in patients with AIDS. 
  • Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for Aspergillus keratitis. 
  • Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei. 
  • Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. 
  • Prevention of amphotericin B-induced rigors by dantrolene. 
  • Prognosis and treatment effects of HIV-associated talaromycosis in a real-world patient cohort. 
  • Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. 
  • Purulent pericarditis caused by Candida: report of three cases and identification of high-risk populations as an aid to early diagnosis. 
  • Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. 
  • Recent advances in antifungal pharmacotherapy for invasive fungal infections. 
  • Recovery from disseminated candidiasis in a premature neonate. 
  • Regulatory mechanisms of a chemoattractant receptor on leukocytes. 
  • Retrospective review of amphotericin B use in a tertiary-care medical center. 
  • Risk factors for mortality in patients with mucormycosis. 
  • Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections. 
  • Safety of Inhaled Amphotericin B Lipid Complex as Antifungal Prophylaxis in Lung Transplant Recipients. 
  • Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. 
  • Simple Strategy for Taming Membrane-Disrupting Antibiotics. 
  • Study of renal safety in amphotericin B lipid complex-treated patients. 
  • Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. 
  • Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. 
  • Successfully treated postoperative Candida parakrusei endophthalmitis. 
  • Susceptibility of Aspergillus to 5-fluorocytosine and amphotericin B alone and in combination. 
  • Taming Amphotericin B. 
  • The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. 
  • The Role of Adjunctive Therapies in the Management of Invasive Sino-Orbital Infection. 
  • The use of amphotericin B in nosocomial fungal infection. 
  • Torulopsis glabrata fungemia--a clinical pathological study. 
  • Transductional mechanisms of chemoattractant receptors on leukocytes. 
  • Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole. 
  • Treatment of experimental disseminated candidiasis with cilofungin. 
  • Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. 
  • Treatment options for invasive fungal infections. 
  • Use of external ventriculostomy and intrathecal anti-fungal treatment in cerebral mucormycotic abscess. 
  • Use of newer antifungal therapies in clinical practice: what do the data tell us? 
  • Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. 
  • When to suspect fungal infection in neonates: A clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. 
  • Zygomycosis caused by Cunninghamella bertholletiae: mycologic aspects. 
  • Zygomycosis: the re-emerging fungal infection.